Feasibility of Aggressive Albuminuria Reduction in Biopsy-Proven Diabetic Nephropathy - a Pilot Study
NCT05897372 on ClinicalTrials.gov · last registry update 2024-09-25
Stopped early, having planned 1 participants. The sponsor logged completion for 23 September 2024. Primary outcome, as filed: urine albumin/creatinin-ratio (UACR) reduction to less than 50% of baseline. semaglutide is approved in the US, but not for diabetic kidney disease — a registration here is not an approval, and most drugs tested in a new condition never get one for it.
- Status
- TERMINATED
- Phase
- P2
- Drug
- semaglutideOzempic, Rybelsus, Wegovy
- Sponsor
- Iain Bressendorff
- Sponsor type
- Other
- Enrollment
- 1
- Started
- 2023-08-01
- Primary completion
- 2024-09-23 actual
Observed history
No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.
Primary outcome
urine albumin/creatinin-ratio (UACR) reduction to less than 50% of baseline
Conditions studied
Diabetic Kidney Disease
Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.